BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34625433)

  • 1. Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma.
    Goldfarb JA; Ferrarotto R; Gross N; Goepfert R; Debnam JM; Gunn B; Nagarajan P; Esmaeli B
    Br J Ophthalmol; 2023 Mar; 107(3):320-323. PubMed ID: 34625433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
    Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
    Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
    In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
    Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
    JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
    Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
    Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
    Giri A; Bauman JR
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
    Ascierto PA; Schadendorf D
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
    Benzaquen M
    Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
    Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors to treat cutaneous malignancies.
    Barrios DM; Do MH; Phillips GS; Postow MA; Akaike T; Nghiem P; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1239-1253. PubMed ID: 32461079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
    Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD
    Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune Checkpoint Inhibition in Marjolin Ulcer: A Case Series.
    Shalhout SZ; Kaufman HL; Sullivan RJ; Lawrence D; Miller DM
    J Immunother; 2021 Jul-Aug 01; 44(6):234-238. PubMed ID: 34100836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
    Wessely A; Steeb T; Leiter U; Garbe C; Berking C; Heppt MV
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
    Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Non-melanoma Skin Cancer.
    Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
    Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Cutaneous Squamous Cell Carcinoma: Italian Multicentric Retrospective Analysis of Patient Profiles and Therapeutic Approaches.
    Mannino M; Piccerillo A; Dika E; Vaccari S; Quaglino P; Rubatto M; Longo C; Borsari S; Pellacani G; Fargnoli MC; Caponio C; Argenziano G; Briatico G; Bianchi L; Di Raimondo C; Calzavara Pinton PG; Zalaudek I; Di Stefani A; Peris K
    Dermatology; 2023; 239(3):422-428. PubMed ID: 36921583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Hernández-Guerrero T; Doger B; Moreno V
    Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis.
    Aboul-Fettouh N; Chen L; Ma J; Patel J; Silapunt S; Migden M
    Australas J Dermatol; 2022 Feb; 63(1):36-42. PubMed ID: 34699068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
    Mager L; Gardeen S; Carr DR; Shahwan KT
    Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.